Table 1 Main characteristics of multidrug-resistant organism carriers with bacteraemia
Variable | Non MDR bacteraemia (n = 46) | MDR bacteraemia (n = 52) | Odds Ratio | P value |
|---|---|---|---|---|
Sex (male) | 30 (65.2%) | 31 (59.6%) | 0.70 [0.35; 1.79] | 0.5683 |
Recent (< 3 months) trip in zone with high MDRO prevalencea | 6 (13.0%) | 3 (5.8%) | 0.41 [0.10; 1.74] | 0.2250 |
Prior antimicrobial treatment in last 6 months | 28 (60.9%) | 38 (73.1%) | 1.74 [0.74; 4.09] | 0.2004 |
Urinary indwelling catheter | 19 (41.3%) | 23 (44.2%) | 1.13 [0.51; 2.51] | 0.7704 |
Immunosuppression | 10 (21.7%) | 23 (44.2%) | 2.86 [1.17; 6.95] | 0.0207 |
Severity | 7 (15.2%) | 19 (36.5%) | 3.13 [1.17; 8.36] | 0.0232 |
Primary site of infection | ||||
UTI | 10 (21.7%) | 15 (28.8%) | 1.46 [0.58; 3.67] | 0.4218 |
Intra abdominal infection | 6 (13.0%) | 5 (9.6%) | 0.71 [0.20; 2.50] | 0.5929 |
Bone and joint infection | 4 (8.7%) | 0 (0.0%) | 0.00 [0.00; I] | 0.9710 |
Respiratory tract infection | 2 (4.3%) | 6 (11.5%) | 2.87 [0.55; 14.98] | 0.2113 |
Skin soft tissue infection | 7 (15.2%) | 4 (7.7%) | 0.46 [0.13; 1.70] | 0.2471 |
Catheter line associated infcetion | 10 (21.7%) | 15 (28.8%) | 1.46 [0.58; 3.67] | 0.4218 |
No primary site of infection | 5 (10.9%) | 7 (13.5%) | 1.28 [0.38; 4.33] | 0.6965 |
Colonization MDR pathogen | ||||
Polymicrobial | 15 (32.6%) | 17 (32.7%) | ||
CRE | 1 (2.2%) | 2 (3.8%) | ||
ESBL Escherichia coli | 23 (50.0%) | 17 (32.7%) | 0.49 [0.22; 1.09] | 0.0814 |
Klebsiella spp. | 18 (39.1%) | 25 (48.1%) | 1.44 [0.64; 3.22] | 0.3738 |
ESBL Klebsiella spp. | 17 (37.0%) | 23 (44.2%) | ||
Carba-R Klebsiella spp. | 1 (2.2%) | 1 (1.9%) | ||
CASE Klebsiella spp. | 0 (0.0%) | 1 (1.9%) | ||
Citrobacter spp. | 1 (2.2%) | 2 (3.8%) | 1.80 [0.16; 20.53] | 0.6360 |
ESBL Citrobacter spp. | 1 (2.2%) | 2 (3.8%) | ||
Enterobacter spp. | 5 (10.9%) | 8 (15.4%) | 1.63 [0.45; 5.98] | 0.4590 |
ESBL Enterobacter spp. | 5 (10.9%) | 7 (13.5%) | ||
Carba-R Enterobacter spp. | 0 (0.0%) | 1 (1.9%) | ||
Acinetobacter baumanii | 2 (4.3%) | 3 (5.8%) | 0.43 [0.04; 4.92] | 0.4984 |
ESBL A. baumanii | 1 (2.2%) | 1 (1.9%) | ||
Carba-R A. baumanii | 1 (2.2%) | 1 (1.9%) | ||
Cefta-R A. baumanii | 0 (0.0%) | 1 (1.9%) | ||
Pseudomonas aeruginosa | 2 (4.3%) | 10 (19.2%) | 5.24 [1.08; 25.32] | 0.0395 |
ESBL P. aeruginosa | 0 (0.0%) | 1 (1.9%) | ||
Carba-R P. aeruginosa | 0 (0.0%) | 3 (5.8%) | ||
Cefta-R P. aeruginosa | 2 (4.3%) | 6 (11.5%) | ||
MRSA | 11 (23.9%) | 15 (28.8%) | 1.29 [0.52; 3.19] | 0.5814 |
VRE | 1 (2.2%) | 0 (0.0%) | 0.88 [0.05; 14.51] | 0.9300 |
Type of infections | ||||
Nosocomial | 24 (52.2%) | 38 (73.1%) | 2.49 [1.07; 5.78] | 0.0340 |
Cure rate | 39 (84.8%) | 44 (84.6%) | 0.99 [0.33; 2.97] | 0.9817 |